Tag: compliance

SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo’s Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells.

Dubai, June 17, 2025: VEON Ltd. (Nasdaq: VEON; the “Company” or “VEON”), a global digital operator, today announces that Omiyinka Doris has chosen to step aside from her role as Group General Counsel of the Company effective July 1, 2025. Ms. Doris will continue as a strategic advisor to the Group Chief Executive Officer and will remain based in Amsterdam.

OTTAWA, Ontario, June 17, 2025 (GLOBE NEWSWIRE) -- A new report from the Commission for Complaints for Telecom-television Services (CCTS) reveals how well service providers have fulfilled their obligations to remain in good standing with the CCTS, Canada’s national telecom and TV industry ombuds. The 2024 Compliance Report Cards summarize providers’ compliance with specific requirements that include informing their customers about the CCTS’ free and impartial service, following the rules of CCTS’ complaint-handling process, paying required fees, and sharing necessary financial information with the CCTS.

CARDIFF, United Kingdom, June 17, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific, a point-of-care diagnostics company, announces it has been awarded ISO 13485 certification for its Lodestar DX testing system, a rapid molecular diagnostic platform for urinary tract infections (UTIs). With industry-leading accuracy and speed, Lodestar DX empowers clinicians to diagnose and rule-out infections with precision in a single visit, thereby improving patient outcomes.